Gd-EOB-DTPA enhanced micro-MR imaging of hepatic tumors in H-ras 12V transgenic mice

Academic Radiology

Volumn 18, Issue 1, 2011, Pages 13-19

  Bang, Dong Ho ^a   Park, Seong Hoon ^a   Jun, Hong Young ^a   Moon, Hyung Bae ^a   Kim, Sun Uk ^b   Yu, Dae Yeul ^b   Yoon, Kwon Ha ^a  

^a Wonkwang University School of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Hepatocellular carcinoma; Liver; MR imaging; Transgenic mice

Indexed keywords

GADOXETIC ACID;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; LIVER TUMOR; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOGENE H RAS; PRIORITY JOURNAL; RADIATION DETECTION; REPEAT PROCEDURE; SIGNAL NOISE RATIO; TISSUE SECTION; TRANSGENIC MOUSE; TUMOR VOLUME; WILD TYPE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; GENES, RAS; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; OBSERVER VARIATION;

EID: 78649908802     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2010.08.007     Document Type: Article

References (28)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics. CA Cancer J Clin 2005, 55:74-108.
2. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143-154.
3. Bos J.L. Ras oncogenes in human cancer; a review. Cancer Res 1989, 49:4682-4689.
4. Boguski M.S., McCormick F. Proteins regulating Ras and its relatives. Nature 1993, 366:643-654.
5. Tada M., Omata M., Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 1990, 50:1121-1124.
6. Kida T., Tsuda H., Pairojkul C., et al. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993, 8:312-318.
7. Staib F., Hussain S.P., Hofseth L.F., et al. TP53 and liver carcinogenesis. Hum Mutat 2003, 21:201-216.
8. Gotzmann J., Huber H., Thallinger C., et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci 2002, 115:1189-1202.
9. Frith C.H., Ward J.M. A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol Toxicol 1979, 3:329-351.
10. Reynolds S.H., Stowers S.J., Maronpot R.R., et al. Detection and identification of activated oncogenes in spontaneously occurring benign and malignant hepatocellular tumors of the B6C3F1 mouse. Proc Natl Acad Sci U S A 1986, 83:33-37.
11. Gilbert E., Morel A., Tulliez M., et al. In vivo effects of activated H-ras oncogene expressed in the liver and in urogenital tissues. Int J Cancer 1997, 73:749-756.
12. Hayashi S., Mori I., Nonoyama T., et al. Point mutation of the c-H-ras gene in spontaneous liver tumors of transgenic mice carrying the human c-H-ras gene. Toxicol Pathol 1998, 28:556-561.
13. Sandgren E.P., Quaife C.J., Pinkert C.A., et al. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989, 4:715-724.
14. Tremblay P.J., Pothier F., Hoang T., et al. Transgenic carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues. Mol Cell Biol 1989, 9:854-859.
15. Wang A.G., Moon H.B., Lee M.R., et al. Gender-dependent hepatic alterations in H-ras12V transgenic mice. J Hepatol 2005, 43:836-844.
16. Allport J.R., Weissleder R. In vivo imaging of gene and cell therapies. Exp Hematol 2001, 29:1237-1246.
17. Bulte J.W., Kraitchman D.L. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004, 17:484-499.
18. Fujata M., Yamamoto R., Fritz-Zieroth B., et al. Contrast enhancement with Gd-EOB-DTPA in MR imaging of hepatocellular carcinoma in mice: a comparison with superparamagnetic iron oxide. J Magn Reson Imaging 1996, 6:472-477.
19. Ni Y., Marchal G., Yu J., et al. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 1994, 4:355-363.
20. Moon E.Y., Lee M.R., Wang A.G., et al. Delayed occurrence of H-ras12V-induced hepatocellular carcinoma with long-term treatment with cinnamaldehydes. Eur J Pharmacol 2006, 530:270-275.
21. Kiryu S., Inoue Y., Watanabe M., et al. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine. Magn Reson Imaging 2009, 27:101-107.
22. Pearline R.V., Lin Y., Shen K.J., et al. Alterations in enzymatic functions in hepatocytes and hepatocellular carcinomas from Ras-transduced livers resemble the effects of insulin. Hepatology 1996, 24:838-848.
23. Eguchi A., Nakashima O., Okudaira S., et al. Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology 1992, 15:843-848.
24. Nakanuma Y., Terada T., Ueda K., et al. Adenomatous hyperplasia of the liver as a precancerous lesion. Liver 1993, 13:1-9.
25. Terada T., Nakanuma Y., Hoso M., et al. Fatty macro-regenerative nodule in non-steatotic liver cirrhosis: a morphologic study. Virchows Arch A Pathol Anat Histopathol 1989, 415:131-136.
26. Winter T.C., Takayasu K., Muramatsu Y., et al. Early advanced hepatocellular carcinoma: evaluation of CT and MR appearance with pathologic correlation. Radiology 1994, 192:379-387.
27. Kim J.I., Lee J.M., Choi J.Y., et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 2008, 43:202-210.
28. Narita M., Hatano E., Arizono S., et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009, 44:793-798.